FDA Approvals | Gene therapy

Products regulated by the Food and Drug Administration comprise 25% of American consumer spending. The approaches used to approve these products can be as varied and complex as the products themselves. Such differences are dictated by Federal law and FDA identifies and enforces the relative risks and benefits that the products pose to consumers. These results convey summaries of products approved by FDA, including information about their past history and present status. The information not only applies to New Molecular Entities, but includes FDA approval information pertaining to new ingredients, dosages, therapeutic uses and generic equivalents.

Top 5 innovator ingredients

Top 5 generic ingredients

  • None

Top 5 innovator sponsors

Top 5 generic sponsors

  • None

Note: these approvals are sourced from Drugs@FDA and Purple Book, and do not currently reflect older FDA approvals and/or other evidence of US marketing.

Active Ingredients

Active IngredientInnovator SponsorApproval YearsInnovator YearsInnovatorGenericType
voretigene neparvovecSpark Therapeutics2017201710Gene therapy
golodirsenSarepta Therapeutics2019201910Gene therapy
onasemnogene abeparvovecNovartis2019 - 20252019 - 202520Gene therapy
casimersenSarepta Therapeutics2021202110Gene therapy
etranacogene dezaparvovecCSL Behring2022202210Gene therapy
lentiglobin bb305bluebird bio2022202210Gene therapy
nadofaragene firadenovecFerring2022202210Gene therapy
beremagene geperpavecKrystal Biotech, Inc.2023202310Gene therapy
delandistrogene moxeparvovecSarepta Therapeutics2023202310Gene therapy
lovotibeglogene autotemcelbluebird bio2023202310Gene therapy
valoctocogene roxaparvovecBiomarin2023202310Gene therapy
Eladocagene ExuparvovecPTC Therapeutics2024202410Gene therapy
fidanacogene elaparvovecPfizer2024202410Gene therapy
13 ingredients
Page 1 / 1

Approval Applications

Appl NoTypeApprovalSponsorActive IngredientsMarketing StatusClassPriority?Links

Submission class glossary

TYPE 1
New Molecular Entity
TYPE 2
New Active Ingredient
TYPE 3
New Dosage Form
TYPE 4
New Combination
TYPE 5
New Formulation or New Manufacturer
TYPE 6
New Indication (pre-2009)
TYPE 7
Drug Already Marketed without Approved NDA
TYPE 8
Partial Rx to OTC Switch
TYPE 9
New Indication or Claim (existing NDA)
TYPE 10
New Indication or Claim (additional NDA)
MEDGAS
Medical Gas